Effect of Monoclonal Antibody Treatment on Clinical Outcomes in Ambulatory Patients With Coronavirus Disease 2019.

Blake AndersonZirka SmithSrilatha EdupugantiXiaobo YanChristopher M MasiHenry M Wu

Published in: Open forum infectious diseases (2021)

We compared rates of emergency department visits or hospitalizations among ambulatory coronavirus disease 2019 (COVID-19) patients treated with monoclonal antibody (mAb) therapy (n = 305) vs untreated patients (n = 6354). Treatment was associated with decreased encounters within 30 days (adjusted odds ratio, 0.23 [95% confidence interval, .15-.36]). Our findings support treatment of acute COVID-19 with mAbs.

Keyphrases

coronavirus disease
monoclonal antibody
emergency department
sars cov
blood pressure
newly diagnosed
stem cells
ejection fraction
hepatitis b virus
drug induced
acute respiratory distress syndrome
cell therapy